Basic Information Experimental Physicochemical Property Pharmacokinetic/Toxicokinetic Property Maximum Dosage Drug Property Radar Chart

Basic Information

Drug ID DDPD00722 ...
Drug Name Lisinopril
Molecular Weight 405.4879
Molecular Formula C21H31N3O5
CAS Number 76547-98-3
SMILES NCCCC[C@H](N[C@@H](CCC1=CC=CC=C1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O
External Links
DRUGBANK DB00722
PubChem Compound 5362119
PDR 23935
Drugs.com Drugs.com Drug Page

Experimental Physicochemical Property

Property Name Property Value Unit Raw Value Raw Unit Reference
Log P -1.01 - -1.01 - MERCK INDEX (1996); pH 7
Melting Point 148.0 ℃ 148 ℃ ChemSpider
Water Solubility 97000.0 mg/L 97000 mg/L MERCK INDEX 1996)
pKa 2.5 - 2.5 - MERCK INDEX (1996)

Pharmacokinetic/ Toxicokinetic Property

Property Name Property Value Unit Raw Value Raw Unit Annotation Factor Reference
Bioavailability 25.0 % 25±20 % PO, oral; The Pharmacological Basis of Therapeutics
Bioavailability 100.0 % 100.0 % PO, oral; The Pharmacological Basis of Therapeutics
C Max 50.0 ng/ml 50(6.4-343) ng/ml PO, oral; adults; hypertension; RD, renal impairment, Renal disease，including uremia; The Pharmacological Basis of Therapeutics
C Max 608231.9 ng/ml 1-2 mM Oral single dose; immediate release formulation; The Pharmacological Basis of Therapeutics
C Max 385213.5 ng/ml 0.7-1.2 mM extended release formulation; The Pharmacological Basis of Therapeutics
T Max 7.0 h ~7 h PO, oral; adults; hypertension; RD, renal impairment, Renal disease，including uremia; The Pharmacological Basis of Therapeutics
T Max 1.8 h 0.5-3 h Oral single dose; immediate release formulation; The Pharmacological Basis of Therapeutics
T Max 4.0 h 2-6 h extended release formulation; The Pharmacological Basis of Therapeutics
Metabolic 0 % 0 % DRUGBANK
Metabolic 100.0 % 100 % Unchanged drug; DRUGBANK
Clearance 10.0 L/h 10.0 L/h Children; RD, renal impairment, Renal disease，including uremia ↓ ; DRUGBANK
Clearance 7.3 L/h 121.0 ml/min Renal clearance; normal,healthy; adults; Male, men; DRUGBANK
Clearance 0.25 L/h/kg 4.2±2.2 ml/min/kg apparent clearance;  Female, women → ;Elderly ↓ ;RD, renal impairment, Renal disease，including uremia ↓ ;congestive heart disease ↓ ; The Pharmacological Basis of Therapeutics
Clearance 0.0720 L/h/kg 1.2 ml/min/kg intravenous injection, IV; human, homo sapiens; Human Intravenous Pharmacokinetic Dataset
Volume of Distribution 124.0 L 124.0 L Apparent volume of distribution; DRUGBANK
Volume of Distribution 2.4 L/kg 2.4±1.4 L/kg Apparent volume of distribution; Elderly → ;RD, renal impairment, Renal disease，including uremia → ; The Pharmacological Basis of Therapeutics
Volume of Distribution 0.89 L/kg 0.89 L/kg intravenous injection, IV; human, homo sapiens; Human Intravenous Pharmacokinetic Dataset
Half-life 12.6 h 12.6 h effective half-life; DRUGBANK
Half-life 46.7 h 46.7 h terminal half-life; DRUGBANK
Half-life 12.0 h 12.0 h effective half-life; at steady state; Multiple dose; RD, renal impairment, Renal disease，including uremia ↑ ;Age ↑ ; The Pharmacological Basis of Therapeutics
Half-life 30.0 h 30.0 h terminal half-life; The Pharmacological Basis of Therapeutics
Half-life 42.0 h 42 h intravenous injection, IV; human, homo sapiens; Human Intravenous Pharmacokinetic Dataset
Toxicity LD50 8500.0 mg/kg >8500 mg/kg PO, oral; Rattus, Rat; DRUGBANK
Toxicity LD50 9100.0 mg/kg >9100 mg/kg PO, oral; mouse; DRUGBANK
Toxicity LDLo 0.0750 mg/kg/day 1200.0 ug/kg/16D PO, oral;  Female, women; DRUGBANK
Toxicity LDLo 12943.0 mg/kg/day 43.0 mg/kg/43W PO, oral; Male, men; DRUGBANK
Eliminate Route 100.0 % 100 % Urinary excretion; DRUGBANK
Eliminate Route 94.0 % 88-100 % Urinary excretion; Unchanged drug; The Pharmacological Basis of Therapeutics
Eliminate Route 95.0 % 95±15 % Urinary excretion; Unchanged drug; The Pharmacological Basis of Therapeutics
Protein Binding 0 % 0 % The Pharmacological Basis of Therapeutics
Protein Binding 0 % 0 % The Pharmacological Basis of Therapeutics

Maximum Dosage

Property Name Property Value Unit Raw Value Raw Unit Annotation Brand Name Component Reference
Max dose for infants 0.36 mg/kg/day 0.36 mg/kg/day PO, oral Qbrelis lisinopril PDR
Max dose for children 0.6 mg/kg/day 0.6 mg/kg/day PO, oral Qbrelis lisinopril PDR
Max dose for children 40.0 mg/day 40 mg/day PO, oral Qbrelis lisinopril PDR
Max dose for children 0.6 mg/kg/day 0.6 mg/kg/day PO, oral Qbrelis lisinopril PDR
Max dose for children 40.0 mg/day 40 mg/day PO, oral Qbrelis lisinopril PDR
Max dose for children 0.6 mg/kg/day 0.6 mg/kg/day PO, oral Qbrelis lisinopril PDR
Max dose for children 0.185 mg/kg/day 0.185 mg/kg/day PO, oral Qbrelis lisinopril PDR
Max dose for children 0.36 mg/kg/day 0.36 mg/kg/day PO, oral Qbrelis lisinopril PDR
Max dose for adolescents 0.6 mg/kg/day 0.6 mg/kg/day PO, oral Qbrelis lisinopril PDR
Max dose for adolescents 40.0 mg/day 40 mg/day PO, oral Qbrelis lisinopril PDR
Max dose for adults 80.0 mg/day 80 mg/day PO, oral Qbrelis lisinopril PDR
Max dose for adults 40.0 mg/day 40 mg/day PO, oral Qbrelis lisinopril PDR
Max dose for geriatric 80.0 mg/day 80 mg/day PO, oral Qbrelis lisinopril PDR
Max dose for geriatric 40.0 mg/day 40 mg/day PO, oral Qbrelis lisinopril PDR

Drug Property Radar Chart

...

Note: Center: Q1-1.5*IQR, Edge: Q3+1.5*IQR; Q1: Quantile 1, Q3: Quantile 3, IQR: Q3-Q1